Understanding the mechanism(s) by which AMPK inhibition halts medulloblastoma cell proliferation and survival may allow the design of potential targeted therapies that exploit the role of AMPK in SHH-driven medulloblastoma and other cancers. Here, PRKAA2 is linked to cancer.